Trial Profile
Phase II study of stereotactic radiotherapy combined with an anlotinib in the treatment of spinal malignant tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 28 Aug 2018 New trial record